UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
For the
month of November, 2010
Commission
File Number: 000-51310
XTL Biopharmaceuticals
Ltd.
(Translation
of registrant’s name into English)
85
Medinat Hayehudim St., Herzliya
Pituach,
PO Box 4033,
Herzliya 46140,
Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.
Form
20-F X
Form
40-F
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): ____
Indicate
by check mark whether by furnishing the information contained in this Form, the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No X
If “Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82- N/A
Incorporation
by Reference: This Form 6-K of XTL Biopharmaceuticals Ltd. dated November 30,
2010 is hereby incorporated by reference into the registration statements on
Form F-3 (File No. 333-141529, File No. 333-147024 and File No. 333-153055)
filed by XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission
on March 23, 2007 , October 30, 2007 and August 15, 2008, respectively, and the
registration statements on Form S-8 (File No. 333-148085, File No. 333-148754
and File No. 333-154795) filed by XTL Biopharmaceuticals Ltd. with the
Securities and Exchange Commission on December 14, 2007, January 18, 2008, and
October 28, 2008, respectively.
XTL
Biopharmaceuticals Announces
Submission
of Draft Shelf Prospectus
Attached hereto
is an English translation (from Hebrew) of an announcement that XTL
Biopharmaceuticals Ltd. has filed a draft shelf prospectus with the Israel
Securities Authority (ISA) and Tel Aviv Stock Exchange (TASE).
XTL Biopharmaceuticals,
Ltd.
(the
“Company”)
November
30, 2010
|
The
Tel Aviv Stock Exchange Ltd.
Via Magna
|
The
Securities Authority
Via
Magna
|
Dear
Sirs,
Re: Immediate
Report
Re: XTL
Biopharmaceuticals Ltd. (“the Company”) –
Submission of Draft Shelf
Prospectus to the Israel Securities Authority
On
November 30, 2010, the Company filed with the Israel Securities Authority (ISA)
and Tel Aviv Stock Exchange (TASE) a draft shelf prospectus on the basis of its
financial statements for the period ending September 30, 2010. According to the
shelf prospectus, the Company will be allowed to offer shares, a number of
series of bonds, a number of series of options to bonds, and
options. The scope and conditions will be set forth in the shelf
registration reports that the Company shall publish in the future, subject to
their publication.
The draft
shelf prospectus submitted does not include an immediate fund raising at this
stage.
Respectfully,
XTL
Biopharmaceuticals, Ltd.
Contact:
Investor
Relations, XTL Biopharmaceuticals Ltd.
Tel: +972
9 955 7080, Email: ir@xtlbio.com
Cautionary
Statement
Some of
the statements included in this Form 6-K may be forward-looking statements that
involve a number of risks and uncertainties. For those statements, we claim the
protection of the safe harbor for forward-looking statements contained in the
Private Securities Litigation Reform Act of 1995.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
| XTL BIOPHARMACEUTICALS LTD. | |||
|
Date:
November 30, 2010
|
By:
|
/s/ David Grossman | |
| David Grossman | |||
| Chief Executive Officer | |||